Klinische Studien

Für Patienten

In unserem Studienzentrum liegt der Schwerpunkt auf Studien der Phase II und III.

aktuelle klinische Studien zu folgenden Indikationen:

Prostatakarzinom
Clinical study to prove the positive healthcare effect of the Uroletics® app in patients with prostate cancer	EUPROS
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide with Continued Versus Intermittent Androgen-Deprivation Therapy (ADT) following PSA Response in Participants with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)	LIBERTAS
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents	Evopar
Urothelkarzinom (Harnblase und oberer Harntrakt)
A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder who are not Receiving Radical Cystectomy	SunRISe-2
A Study of Pembrolizumab (MK3475) Plus V940 in Participants With Bladder Cancer Post-Radical Resection	V940-005
Nierenzellkarzinom
A Randomized Open Label Phase II Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients with Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma	BO43936
Virtual Interactive 3D Modelling to improve Outcomes in Robotic-Assisted Partial Nephrectomy – A Multicentre, Randomised, Controlled Trial	3DPN

weitere Informationen finden Sie unter: ClinicalTrials.gov

Sofern Sie in diesem Zusammenhang Fragen haben oder eventuell an einer der Studien in unserer Klinik teilnehmen möchten, setzen Sie sich bitte mit uns in Verbindung.

Kontakt:

Klinische Studien

Pit Raupach, B.A.